Title: Money Today-- Pathway to transfer super-antibiotic technology for LegoChem opens

Publication: Money Today/ Dong Hee Kim

Date: 15 October 2015

Summary

• The possibility of LegoChem successfully tranferring the gram-negative super-antibiotic technology has increased. It's because the antibiotic LCB10-0200 that is in the nonclinical phase in UK and the BLI candidate substance LCB18-0064 have been successfully developed and can be packaged. If LegoChem were to transfer both of these technology together, it could be a big deal expecting more than one trillion Korean won.

• LegoChem still has to go through nonclinical phase, but they are starting off in a positive climiate. The research team analyzed that that their BLI technology is more effective than their compeititors'.

• CEO Yong Zu Kim said, “Through developing BLI candidate substance, we have a big weapon to enter the global market."

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).